Weight Loss$30–$80

AOD-9604: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 9 sources cited

Overview

AOD-9604 is a modified 16-amino-acid fragment of human growth hormone (corresponding to amino acids 176–191 of the hGH sequence) that retains the potent fat-metabolizing properties of growth hormone while completely lacking its growth-promoting, diabetogenic, and IGF-1-elevating effects. Developed at Monash University in Australia, it stimulates lipolysis and inhibits lipogenesis through a mechanism distinct from full-length GH, making it one of the most targeted and well-characterized anti-obesity peptides available. It is not approved by any regulator for any use, and its cartilage-regenerative properties come from animal work.

Mechanism of Action

AOD-9604 operates through a unique mechanism that selectively activates the lipolytic pathway of growth hormone signaling without engaging the broader GH receptor cascade. It does not act directly on the beta-3 adrenergic receptor (β3-AR) on adipocytes, the main lipolytic receptor on fat cells: in obese mice it raises β3-AR expression, and in β3-AR knockout mice the weight loss and lipolysis seen in normal mice did not occur. Lipolysis itself runs through hormone-sensitive lipase (HSL). HSL catalyzes the hydrolysis of stored triglycerides, releasing free fatty acids and glycerol for oxidation. Simultaneously, AOD-9604 inhibits lipogenesis (new fat synthesis) by reducing the activity of two key lipogenic enzymes: acetyl-CoA carboxylase (ACC) and fatty acid synthase (FAS) in adipose tissue. This dual action — enhanced fat breakdown plus reduced fat creation — produces a net reduction in adipose tissue mass that is more targeted than what full-length GH achieves. The critical pharmacological advantage of AOD-9604 is what it does NOT do. Because it is a fragment comprising only the C-terminal loop of GH (stabilized by a disulfide bond between Cys182 and Cys189, with a tyrosine modification), it does not activate the JAK2-STAT5 signaling pathway that drives IGF-1 production, cell proliferation, and insulin resistance. This means: no increase in IGF-1 levels (eliminating cancer proliferation concerns), no hyperglycaemia in the mouse studies and no change in glucose tolerance in the human trials, no organ or bone growth, and no water retention. It is purely lipolytic. Additionally, in a rabbit model of osteoarthritis, weekly injections of AOD-9604 into the knee joint improved cartilage scores, and worked better combined with hyaluronic acid than either alone. No human trial of AOD-9604 for osteoarthritis is registered on ClinicalTrials.gov.

AOD-9604 Benefits: What the Research Shows

  • The Phase IIb trial, a 24-week oral study in obese adults (534 enrolled, 502 randomized), failed to show a significant benefit on its primary weight-loss endpoint, and the sponsor ended the obesity program.
  • Across six placebo-controlled trials, AOD-9604 had no effect on serum IGF-1 and no negative effect on carbohydrate metabolism on oral glucose tolerance testing, a critical distinction from full-length GH.
  • An intra-articular study in a rabbit model of osteoarthritis found that weekly AOD9604 injections improved cartilage scores, and that AOD9604 with hyaluronic acid worked better than either alone.
  • Studies in Endocrinology and the International Journal of Obesity found that AOD-9604 reduced body weight gain and raised fat oxidation and lipolysis in obese mice without the hyperglycaemia hGH caused, and that it does not bind the GH receptor.
  • In the clinical trial program, no antibodies to AOD-9604 were found in the patients tested.

AOD-9604 Dosage

  • Standard subcutaneous dose: 250–300 mcg once daily, injected into the abdominal subcutaneous fat. The human trials did not inject it under the skin at all: they used oral dosing, or a single intravenous infusion of 25 to 400 mcg.
  • Timing: Inject first thing in the morning on an empty stomach, at least 30 minutes before eating. GH-related peptides are blunted by elevated insulin and blood glucose, so fasted administration is critical for optimal lipolysis.
  • Loading protocol: Some practitioners use 500 mcg/day for the first 2 weeks, then reduce to 250 mcg/day for maintenance. This may accelerate initial results but increases cost.
  • Standard cycle: 12 weeks on, 4 weeks off. AOD-9604 does not cause desensitization in the same way that full GH does, but cycling is recommended to assess ongoing need and maintain receptor sensitivity.
  • Extended protocol: Some users run continuous cycles of 16–20 weeks at 250 mcg/day with positive results and no reported adverse effects. No published trial has run longer than 24 weeks.
  • Stacking with CJC-1295/Ipamorelin: AOD-9604 250 mcg in the morning (fasted), with CJC-1295/Ipamorelin 100 mcg each at bedtime. This covers fat loss (AOD) and GH-mediated recovery/body composition (CJC/Ipa) without overlapping mechanisms.
  • Stacking with 5-Amino-1MQ: AOD-9604 250 mcg SC in the morning + 5-Amino-1MQ 50 mg oral. Different fat loss mechanisms (β3-AR lipolysis + NNMT/NAD+ metabolic enhancement) for additive results.
  • For cartilage/joint applications: 300 mcg daily subcutaneous or intra-articular injection (clinic setting only for IA). Joint-focused protocols typically run 8–12 weeks.
  • Rotate injection sites within the abdominal area to prevent lipodystrophy. Inject at a 45-degree angle with an insulin syringe (29–31 gauge).
AOD-9604 dosage calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

AOD-9604 Side Effects & Safety

Known Side Effects

  • Injection site reactions — mild redness, itching, or transient pain at the injection site. Usually resolves within minutes and diminishes with continued use.
  • Headache — reported infrequently, typically mild and resolving within the first week of use.
  • Mild flu-like symptoms — rare, occurring in the first few days of treatment. May be related to increased metabolic activity or an immune response to the peptide.
  • Transient hypoglycemia — very rare and mild, occurring primarily in individuals who are also fasting or on very low carbohydrate diets. Much less common than with full GH due to the absence of IGF-1/insulin axis effects.
  • Mild water retention — uncommon and much less pronounced than with full GH. Some users report slight bloating in the first week that resolves spontaneously.
  • No serious adverse events related to AOD-9604 were reported in its six placebo-controlled trials. FDA, reviewing it as a compounding ingredient, says it has identified no or only limited safety information for it.

Safety Profile

AOD-9604 has more human safety data than most peptides in research use: six short placebo-controlled trials in which its tolerability was indistinguishable from placebo. Its key safety advantage is mechanistic: by acting exclusively on the C-terminal lipolytic domain of GH without activating the JAK2-STAT5/IGF-1 cascade, it avoids the insulin resistance, organ growth, fluid retention, and cancer proliferation risks associated with exogenous growth hormone. In those trials no serious adverse events were attributed to AOD-9604, serum IGF-1 was unchanged and glucose tolerance testing showed no negative effect. No antibodies to AOD-9604 were found in the patients tested. Contraindications are minimal but include: known hypersensitivity to GH-derived peptides, active malignancy (as a precaution, though AOD-9604 does not raise IGF-1), and pregnancy/breastfeeding (insufficient data). Its trials found no effect on glucose tolerance, but it has not been tested as a treatment in people with diabetes. No drug interaction studies have been published. Individuals on thyroid replacement should monitor levels, as improved metabolic rate could theoretically alter thyroid hormone requirements. FDA, which reviewed AOD-9604 as a compounding ingredient, says it has identified no or only limited safety information for it, along with serious adverse events whose cause is not clear.

What to Expect

Week 1–2: Subtle metabolic changes begin. Some users report feeling slightly warmer, particularly in the abdominal area after injection. The lipolytic process is initiating at the cellular level. Injection site reactions are most common during this period. No visible body composition changes yet. Weeks 3–4: The first noticeable changes appear. Users typically report reduced abdominal bloating, improved definition around the midsection, and a general sense of metabolic efficiency. Clothes may begin fitting slightly looser around the waist. Fasted morning energy often improves as fat oxidation pathways are upregulated. Weeks 5–8: This is the primary fat loss window. Most users see measurable reductions in waist circumference (0.5–1.5 inches is typical by week 8) and body fat percentage. The effects are most pronounced with concurrent exercise and reasonable nutrition. Visceral fat reduction may be reflected in improved inflammatory markers on blood work. Weeks 9–12: Continued steady fat loss, though the rate typically slows compared to weeks 5–8 as the body approaches a new metabolic set point. Total fat loss over a 12-week cycle is commonly reported by users as 4–8 lbs, though the 24-week trial in obese adults did not beat placebo on weight loss. Joint-focused users may begin noticing improved mobility and reduced stiffness during this phase. Post-cycle, some fat loss benefits persist for 2–4 weeks as the metabolic adaptations gradually revert.

Common Stacks

Storage & Handling

Store lyophilized powder refrigerated at 36–46°F (2–8°C). Protect from light. For long-term storage, freezing at -4°F (-20°C) is acceptable and extends shelf life to 24+ months. After reconstitution with bacteriostatic water (0.9% benzyl alcohol), refrigerate at 36–46°F and use within 4–6 weeks. Use a clean insulin syringe for each withdrawal to maintain sterility. Do not freeze reconstituted solution. Reconstituted vials should be gently swirled (not shaken) when mixing. Typical reconstitution: add 2 mL bacteriostatic water to a 5 mg vial for a concentration of 2.5 mg/mL (250 mcg per 0.1 mL/10 units on an insulin syringe).

Pricing & Available Variants

$30 – $80price range
2mg5mg10mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

Related Peptides

Track AOD-9604 in Your Protocol

Log your AOD-9604 doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free